Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
News|Articles|May 21, 2026
Why High-Concentration Biologics Demand a New Approach to Formulation Science
Author(s)Samsung Biologics
The biopharmaceutical landscape is undergoing a structural shift toward greater molecular complexity and formulation concentrations exceeding 100 mg/mL. High-concentration formulations, particularly those intended for subcutaneous administration, present a distinct set of technical challenges that conventional development approaches were not designed to address. Samsung Biologics’ proprietary S-HiCon™ platform provides an integrated, data-driven framework for navigating these challenges, encompassing early material generation, structured excipient screening, and advanced analytical characterization.
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.